Aimmune Therapeutics, Inc. (AIMT) Is At $35.49 Formed Wedge; Emerge Energy Services LP (EMES)’s Sentiment Is 0.58

Emerge Energy Services LP, through its subsidiary, Superior Silica Sands LLC, operates an energy services firm in the United States. The company has market cap of $253.49 million. It engages in mining, processing, and distributing silica sand, which is a primary input for the hydraulic fracturing of oil and natural gas wells. It currently has negative earnings. The firm serves oilfield services companies, and exploration and production companies that are engaged in hydraulic fracturing.

Aimmune Therapeutics, Inc. (AIMT) formed wedge up with $38.68 target or 9.00% above today’s $35.49 share price. Aimmune Therapeutics, Inc. (AIMT) has $1.82B valuation. The stock increased 0.48% or $0.17 during the last trading session, reaching $35.49. About 32,451 shares traded. Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has risen 32.49% since February 6, 2017 and is uptrending. It has outperformed by 15.79% the S&P500.

Ratings analysis reveals 67% of Emerge Energy Services’s analysts are positive. Out of 3 Wall Street analysts rating Emerge Energy Services, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $12.0 while the high is $15.0. The stock’s average target of $13.50 is 65.04% above today’s ($8.18) share price. EMES was included in 3 notes of analysts from September 29, 2016. Wunderlich upgraded Emerge Energy Services LP (NYSE:EMES) rating on Thursday, September 29. Wunderlich has “Buy” rating and $15.0 target. The firm has “Hold” rating by Stifel Nicolaus given on Wednesday, December 21. Goldman Sachs upgraded the stock to “Buy” rating in Friday, January 20 report.

Analysts await Emerge Energy Services LP (NYSE:EMES) to report earnings on February, 26. They expect $0.31 EPS, up 140.26% or $1.08 from last year’s $-0.77 per share. EMES’s profit will be $9.61 million for 6.60 P/E if the $0.31 EPS becomes a reality. After $0.18 actual EPS reported by Emerge Energy Services LP for the previous quarter, Wall Street now forecasts 72.22% EPS growth.

Yorkville Capital Management Llc holds 2.46% of its portfolio in Emerge Energy Services LP for 257,942 shares. Sg Capital Management Llc owns 150,989 shares or 0.13% of their US portfolio. Moreover, Balyasny Asset Management Llc has 0.05% invested in the company for 1.67 million shares. The Illinois-based Castleark Management Llc has invested 0.05% in the stock. Ing Groep Nv, a Netherlands-based fund reported 200,000 shares.

The stock increased 2.00% or $0.16 during the last trading session, reaching $8.18. About 228,654 shares traded. Emerge Energy Services LP (EMES) has risen 243.72% since February 6, 2017 and is uptrending. It has outperformed by 227.02% the S&P500.

Among 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aimmune Therapeutics had 5 analyst reports since August 31, 2015 according to SRatingsIntel. The company was initiated on Monday, September 26 by JMP Securities. The stock of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has “Buy” rating given on Monday, August 31 by Bank of America. Piper Jaffray initiated it with “Overweight” rating and $35 target in Monday, August 31 report. As per Monday, August 31, the company rating was initiated by Credit Suisse. Piper Jaffray maintained Aimmune Therapeutics, Inc. (NASDAQ:AIMT) rating on Tuesday, November 17. Piper Jaffray has “Overweight” rating and $38.0 target.

Analysts await Aimmune Therapeutics, Inc. (NASDAQ:AIMT) to report earnings on March, 21. They expect $-0.70 earnings per share, down 27.27% or $0.15 from last year’s $-0.55 per share. After $-0.63 actual earnings per share reported by Aimmune Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.